Tafamidis Meglumine

DAE Class; Rx

Common Brand Names; Vyndaqel

• Cardiovascular, Other

Selective stabilizer of transthyretin (TTR) for cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults
Reduces cardiovascular mortality and cardiovascular-related hospitalizations
Potential to cause fetal harm; advise women of child-bearing potential to use contraception during therapy

Indicated for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization

Dosing Considerations

Tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) are not substitutable on a per mg basis

None

–

Cautions

Drug interactions overview

Breast cancer-resistant protein (BCRP) inhibitor

• BCRP substrates

  • Monitor for signs of BCRP substrate-related toxicities and modify dosage of substrate if appropriate
  • Tafamadis increases exposure and risk of toxicities of BCRP substrates

Pregnancy

Based on animal studies, fetal harm may occur when administered to a pregnant woman

Lactation

No data available on the presence of tafamidis in human milk, effect on the breastfed infant, or the effect on milk production

Adults

80 mg once daily (Vyndaqel); 61 mg once daily (Vyndamax).

Geriatric

80 mg once daily (Vyndaqel); 61 mg once daily (Vyndamax).

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Tafamidis Meglumine